ArticleBMC cardiovascular disorders2026
A HEART-WISE: Allogeneic Wharton's Jelly-derived Mesenchymal Stromal Cells' Intracoronary Transplantation in Pediatric Patients with Dilated Cardiomyopathy: The First Case Reports.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPediatric dilated cardiomyopathy (PDCM) is a severe cardiovascular disorder characterized by ventricular systolic dysfunction, with heart transplantation as the gold standard therapy. Mesenchymal stromal cells (MSCs) have demonstrated promise for treating cardiomyopathy, but previous studies in pediatric patients have focused exclusively on autologous cells such as MSCs, while allogeneic MSCs with better results were studied only in adults.
objectiveThe study “A HEART-WISE” is the first case reports to evaluate the safety and feasibility of intracoronary transplantation of allogeneic GMP-complierant Wharton’s jelly-derived MSCs (WJ-MSCs) in PDCM patients.
methodsTwo pediatric patients with PDCM received a single intracoronary infusion of 1.5 × 10⁶ cells/kg WJ-MSCs. Clinical evaluations included NYHA functional class, six-minute walk test (6MWT), N Terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac imaging over a 12-month follow-up period.
resultsBoth patients tolerated intracoronary WJ-MSC administration without serious adverse events related to the procedure. Patient 1 demonstrated marked improvements by 3 months (NYHA III to II, LVEF 33% to 48%, 6MWT 300 to 373 m, NT-proBNP 3502 to 1734 pg/mL) but passed away at 6 months follow-up due to a viral infection. Patient 2 had a persistently reduced LVEF in the 43–46% range for more than three years prior to therapy but achieved sustained improvement by 12 months (NYHA III to II, LVEF 43% to 64%, 6MWT 265 to 380 m).
conclusionOur preliminary findings suggest the safety and feasibility of intracoronary transplantation of allogeneic WJ-MSCs in PDCM, with potential off-the-shelf therapeutic benefit. Validation of these observations in larger randomized controlled trials is needed to better evaluate long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.